Detalhe da pesquisa
1.
Proteomic identification of a marker signature for MAPKi resistance in melanoma.
EMBO J
; 38(15): e95874, 2019 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31267558
2.
Cuticular Poroma: A Rare Poroma Variant Simulating a Malignant Neoplasm That Often Harbors YAP1::NUTM1 Fusions Similar to Their Conventional Counterparts.
Am J Dermatopathol
; 45(8): 544-548, 2023 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37335840
3.
Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland.
J Eur Acad Dermatol Venereol
; 37(5): 894-906, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-36433688
4.
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
Lancet Oncol
; 22(6): 836-847, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33989557
5.
Improved detection of in-transit metastases of malignant melanoma with BSREM reconstruction in digital [18F]FDG PET/CT.
Eur Radiol
; 31(10): 8011-8020, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-33768288
6.
The role of cyclin D1 and Ki-67 in the development and prognostication of thin melanoma.
Histopathology
; 77(3): 460-470, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32374893
7.
Eight autopsy cases of melanoma brain metastases showing angiotropism and pericytic mimicry. Implications for extravascular migratory metastasis.
J Cutan Pathol
; 46(8): 570-578, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-30927294
8.
Update on adjuvant melanoma therapy.
Curr Opin Oncol
; 30(2): 118-124, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29256902
9.
Methadone-Not a magic bullet in melanoma therapy.
Exp Dermatol
; 27(6): 694-696, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29577418
10.
EGFR expression is associated with relapse in a melanoma cohort receiving adjuvant PD-1-based immunotherapy.
J Am Acad Dermatol
; 89(5): 1072-1074, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37487833
11.
Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply.
Lancet Oncol
; 22(8): e343-e344, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34339647
12.
Hair Depigmentation and Hair Loss in Advanced Melanoma Treated with Combined Immunotherapy and Targeted Therapy.
Acta Derm Venereol
; 100(1): adv00007, 2020 Jan 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31626322
13.
Real-World Data on Clinical Outcomes and Treatment Management of Advanced Melanoma Patients: Single-Center Study of a Tertiary Cancer Center in Switzerland.
Cancers (Basel)
; 16(5)2024 Feb 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38473216
14.
Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy.
Eur J Cancer
; 196: 113425, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38039778
15.
The features and management of acquired resistance to PD1-based therapy in metastatic melanoma.
Eur J Cancer
; 196: 113441, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37988842
16.
Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy.
Eur J Cancer
; 199: 113563, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38278007
17.
Cutaneous Adverse Events of Systemic Melanoma Treatments: A Retrospective Single-Center Analysis.
Pharmaceuticals (Basel)
; 16(7)2023 Jun 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37513847
18.
Clock-like Mutation Signature May Be Prognostic for Worse Survival Than Signatures of UV Damage in Cutaneous Melanoma.
Cancers (Basel)
; 15(15)2023 Jul 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37568633
19.
Treatment reality of patients with BRAF-mutant advanced/metastatic melanoma in Switzerland in the era of choice.
Melanoma Res
; 32(5): 366-372, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35855650
20.
Impact of Covid-19 on the management of patients with metastatic melanoma.
Oncotarget
; 13: 1370-1379, 2022 12 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-36580495